1.MicroRNA isomiRs reveal novel pathways linked to disease activity and fibrosis in MASLD
Christian BRION ; Stephen Aurelien HOANG ; Guangliang WANG ; Faridodin MIRSHAHI ; Jessie ANG ; Matthew Ray LONG ; Zheng ZHU ; Bhanu SAKHAMURI ; Molly Anderson SROUR ; Mohammad Shadab SIDDIQUI ; Amon ASGHARPOUR ; David John HAYES ; Neal Charles FOSTER ; David William SALZMAN ; Arun Jayant SANYAL
Clinical and Molecular Hepatology 2026;32(2):706-720
Background/Aims:
MicroRNA (miRNA) isoforms (isomiRs) broaden the regulatory landscape of canonical miRNAs, but their role in metabolic dysfunction-associated steatotic liver disease (MASLD) remains unknown. We aimed to characterize the hepatic isomiR landscape in MASLD and define their association with disease activity and fibrosis.
Methods:
Small RNA (sRNA) sequencing was performed on liver biopsies from 79 patients across the histological spectrum of MASLD. IsomiRs were annotated and quantified. Their association to disease activity and fibrosis score was assessed by differential expression, ordinal regression, and machine learning. Parallel mRNA sequencing and pathway enrichment were used to map isomiR–mRNA interactions and regulatory networks, which were validated against an independent dataset.
Results:
MiRNAs accounted for 75% of sRNAs in liver tissue, of which 67% were isomiRs. Across MASLD severity, 173 isomiRs correlated with disease activity and 58 with fibrosis stage. Key findings included a miR-122 isomiR uniquely targeting INSIG1 (cholesterol metabolism) and a miR-21 isomiR targeting PPARA and HMGCS2 (lipid and fibrosis pathways). Integration with mRNA data revealed 33 dysregulated pathways, including PPAR signaling, insulin resistance, and TGF-β response. Several novel isomiRs from miR-26b, let-7c, and miR-32 families were also linked to lipid metabolism and fibrosis progression.
Conclusions
IsomiRs represent the majority of hepatic miRNAs and uncover novel regulatory networks masked by canonical miRNA analysis. These findings provide new insights into the molecular heterogeneity of MASLD, highlight candidate pathways driving disease progression, and identify potential biomarkers and therapeutic targets for precision hepatology.
Result Analysis
Print
Save
E-mail